Skip to main content
. 2017 Jun 10;26(17):1000–1008. doi: 10.1089/ars.2016.6809

FIG. 3.

FIG. 3.

NOSTRIN is a predictor of prognosis in early stage resected patients with PDAC. Patients with a higher NOSTRIN expression in tumors survive longer compared with patients with a lower expression of NOSTRIN. NOSTRIN inhibits NOS3 (eNOS) and reduces NO production. NOSTRIN, endothelial nitric oxide synthase traffic inducer; PDAC, pancreatic ductal adenocarcinoma. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars